RNAC vs. PDSB, SGMT, ACET, NVCT, SYRS, AMLX, SKYE, KPTI, DMAC, and RZLT
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include PDS Biotechnology (PDSB), Sagimet Biosciences (SGMT), Adicet Bio (ACET), Nuvectis Pharma (NVCT), Syros Pharmaceuticals (SYRS), Amylyx Pharmaceuticals (AMLX), Skye Bioscience (SKYE), Karyopharm Therapeutics (KPTI), DiaMedica Therapeutics (DMAC), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
PDS Biotechnology (NASDAQ:PDSB) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
PDS Biotechnology has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
In the previous week, Cartesian Therapeutics had 16 more articles in the media than PDS Biotechnology. MarketBeat recorded 27 mentions for Cartesian Therapeutics and 11 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.51 beat Cartesian Therapeutics' score of 0.42 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
PDS Biotechnology has higher earnings, but lower revenue than Cartesian Therapeutics.
PDS Biotechnology has a net margin of 0.00% compared to PDS Biotechnology's net margin of -983.93%. PDS Biotechnology's return on equity of -58.21% beat Cartesian Therapeutics' return on equity.
PDS Biotechnology currently has a consensus price target of $17.33, suggesting a potential upside of 382.82%. Cartesian Therapeutics has a consensus price target of $45.00, suggesting a potential upside of 109.79%. Given Cartesian Therapeutics' higher possible upside, equities analysts clearly believe PDS Biotechnology is more favorable than Cartesian Therapeutics.
26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 10.0% of PDS Biotechnology shares are owned by company insiders. Comparatively, 31.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
PDS Biotechnology received 51 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 67.05% of users gave PDS Biotechnology an outperform vote.
Summary
Cartesian Therapeutics beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
